Horizon Discovery signs master service deal with top three global pharmaceutical firm

Adding to a pre-existing MSA for in vivo services, the terms of this agreement now covers a range of Horizon’s in vitro service offerings, defining the pricing and terms that will govern future transactions and facilitating simplified entry into forthcoming agreements.

Services included under the MSA are: custom cell line engineering, target identification and validation screening (including the use of CRISPR gene editing technology), drug combination screening, and cell-based assay services.

Horizon is establishing itself as a key provider to an increasing number of major pharmaceutical and biotech companies by delivering reliable, high-quality, high-value services, and by strengthening key relationships within each organisation. 

In this way, Horizon was able to negotiate this agreement, building trust with the Company and becoming a preferred provider over time. It is now Horizon’s single largest customer, contributing over £1.5m in revenue in 2016 (£0.6 million FY15) and the current project pipeline indicates there will be an expansion of revenue received in 2017.

Horizon Discovery CEO Dr. Darrin Disley said: “Today’s announcement demonstrates the success of Horizon’s strategy of deepening relationships with our top customers. By taking a broader and more integrated approach, we are able to identify areas where we can provide significant value and are able to offer unified solutions that involve a range of Horizon’s services.

“In 2016, our top 20 customers provided over £9.8m to the Group, and in 2017 we are looking to increase our revenue from this segment by at least 20%, with this agreement serving as a template.”